Table 3.
Factors associated with progression‐free survival, subgroup analysis by type of subsequent chemotherapy
| Variable | sPBC, risk of progression | sNPBC, risk of progression | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | Standard error | χ2 | HR (95% CI) | Standard error | χ2 | |
| ECOG PS | ||||||
| 1 vs. 0 | 0.97 (0.61–1.52) | 0.23 | 0.883 | 1.01 (0.67–1.51) | 0.20 | 0.970 |
| ≥2 vs. 0 | 1.18 (0.53–2.65) | 0.41 | 0.683 | 2.03 (1.28–3.22) | 0.24 | 0.003 |
| Unknown vs. 0 | 1.19 (0.69–2.06) | 0.28 | 0.530 | 1.06 (0.66–1.72) | 0.25 | 0.802 |
| CCI | ||||||
| 1 vs. 0 | 0.98 (0.52–1.83) | 0.32 | 0.937 | 2.22 (1.19–4.14) | 0.32 | 0.013 |
| 2 vs. 0 | 0.98 (0.52–1.82) | 0.32 | 0.942 | 0.84 (0.53–1.33) | 0.23 | 0.464 |
| ≥3 vs. 0 | 1.01 (0.67–1.53) | 0.21 | 0.947 | 1.39 (0.88–2.17) | 0.23 | 0.155 |
| Liver metastases | ||||||
| Yes vs. no | 1.78 (1.14–2.79) | 0.23 | 0.011 | 0.97 (0.68–1.39) | 0.18 | 0.859 |
| Unknown vs. no | 0.35 (0.07–1.84) | 0.85 | 0.214 | 1.07 (0.57–1.99) | 0.32 | 0.839 |
| Number of fPBC cycles | 1.10 (0.94–1.29) | 0.08 | 0.248 | 1.21 (1.07–1.38) | 0.07 | 0.003 |
| Best response to fPBC | ||||||
| PR vs. CR | 1.42 (0.72–2.81) | 0.35 | 0.313 | 0.82 (0.41–1.66) | 0.36 | 0.580 |
| SD vs. CR | 2.75 (1.32–5.72) | 0.37 | 0.007 | 0.88 (0.42–1.86) | 0.38 | 0.738 |
| PD vs. CR | 2.15 (0.95–4.87) | 0.42 | 0.066 | 1.49 (0.68–3.27) | 0.40 | 0.320 |
| Unknown vs. CR | 1.17 (0.46–3.00) | 0.48 | 0.747 | 1.76 (0.75–4.09) | 0.43 | 0.193 |
| Months elapsed since fPBC | 0.98 (0.94–1.02) | 0.02 | 0.295 | 0.99 (0.97–1.01) | 0.01 | 0.381 |
Abbreviations: CI, confidence interval; CCI, Charlson Comorbidity Index; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; fPBC, first‐line platinum‐based chemotherapy; HR, hazard ratio; PD, progressive disease; PR, partial response; SD, stable disease; sNPBC, subsequent non–platinum‐based chemotherapy; sPBC, subsequent platinum‐based chemotherapy.